ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SN. Smith & Nephew Plc

1,122.00
-3.00 (-0.27%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00 -0.27% 1,122.00 1,125.50 1,126.50 1,132.00 1,121.00 1,123.00 3,601,342 16:35:04
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Ortho,prosth,surg Appl,suply 5.55B 263M 0.3008 37.42 9.84B
Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,125p. Over the last year, Smith & Nephew shares have traded in a share price range of 887.00p to 1,215.50p.

Smith & Nephew currently has 874,320,227 shares in issue. The market capitalisation of Smith & Nephew is £9.84 billion. Smith & Nephew has a price to earnings ratio (PE ratio) of 37.42.

Smith & Nephew Share Discussion Threads

Showing 1051 to 1074 of 1350 messages
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
DateSubjectAuthorDiscuss
29/10/2021
13:30
(RTTNews) - Shares of Stryker Corp. (SYK) slipped over 3% in extended trading session on Thursday after the company lowered its full year 2021 outlook.

The company now expects full year organic net sales growth of 7% to 8% compared to 2019, and adjusted earnings of $9.08 to $9.15 per share.

Previously, the company expected organic net sales growth of 9% to 10% from 2019, and adjusted earnings of $9.25 to $9.40 per share.

philanderer
29/10/2021
13:07
SN. Updates next week
value viper
29/10/2021
13:07
berenberg noted a few weeks ago sums it up nicely "firm was now facing a "bumpier road" to the "same destination""
"Thus, if we only took a short-term view, we would find it hard to recommend buying Smith & Nephew's shares, but they are so undervalued, in our view, that we simply view any near-term volatility as an opportunity," said the analysts.

so this isnt an overnight play, but if management can execute, there should be considerable upside on, i would say, a 2 or 3 year timeframe.

roguetraderuk
29/10/2021
13:07
Stryker (US) guides lower I understand- need to buy SN. !!
value viper
29/10/2021
12:10
Dividend reinvestment a.


SN, is selling on 22.5 X FY 2022 and I'm guessing FY forecasts will be reduced.


So yes it's a bargain, ain't it ;

essentialinvestor
29/10/2021
11:24
Been buying today....looks a good opportunity and I also see a few director buys....some only mentions the sells and forgets to mention the buys ;-)
laptop15
29/10/2021
10:35
1200p looks like a good psychological level for a pause.
bigbertie
29/10/2021
09:27
Elective surgeries are being delayed which is bad news for them.
Overall demographic trends are in their favour but short term issues.
I have them on my watch list but expect another final down leg.

salpara111
29/10/2021
09:05
One director after another selling as I've highlighted.
essentialinvestor
29/10/2021
09:04
Warning from US rival according to Telegraph
malcolm caton
29/10/2021
08:53
I'm sure it has nothing to do with results next week ) - let's see.
essentialinvestor
29/10/2021
08:37
Doesn't seem to be, just market makers making a market I think
laptop15
29/10/2021
08:22
Any reason for this drop today.
csalvage
14/10/2021
17:27
Nice to see this go up but can't see any news.
csalvage
06/10/2021
12:03
New 1 year low hit and downward momentum at 1237 - Will £12.00 hold or retreat below the lows of last year at about £11.50?
pugugly
05/10/2021
11:01
BARCLAYS CUTS SMITH & NEPHEW PRICE TARGET TO 1,760 (1,775) PENCE - 'OVERWEIGHT'
philanderer
04/10/2021
17:17
7,000 admissions was the very top end and always looked uber pessimistic,
modelled range was 2,000-7,000, fortunately we are well below the low end atm.

essentialinvestor
04/10/2021
11:32
CITIGROUP CUTS SMITH & NEPHEW PRICE TARGET TO 1,420 (1,610) PENCE - 'NEUTRAL'
philanderer
03/10/2021
13:02
AS&SB - Thanks for input.
pugugly
03/10/2021
10:21
So given the above numbers - which are very encouraging - the NHS should begin to pull its finger out.
Suet

suetballs
03/10/2021
09:43
pugugly, re covid uncertainty, the number of red list travel destinations are due to be slashed because Covid-19 hospitalisation rates have confounded modelling which suggested that daily admissions could number 7,000 this month, when in fact they appear to have plateaued at 600. This reduced burden on the NHS, coupled with the 1 in 5 patients on the NHS routine operation waiting list going private, should start to reflect in improved figures for S&N as early as the Nov 4th update. As for the fly season
aquaesulis01
01/10/2021
17:29
Now I wonder if I called the bottom with post 457 - Have been tracking for over the summer but establing an apparent pattern of 1 step up and then 2 steps down,since July. Will 1200p hold. NEGK.
pugugly
01/10/2021
11:17
Suet you are not the only one in this position!

When you see Myra Eskes Pres of APAC region selling a lot of stock you do wonder what they know that we don't. The results seemed ok and forward looking it seemed all ok.

Or is it just an II needing to raise cash? But I then expect an RNS about holdings every day.

gclark
01/10/2021
10:20
Increasing my holding here was not one of my better decisions!
This is a very unloved stock and Mr Market has shown no mercy.
As to the eventual low I hope it won't go sub £12 which is the level it reached when covid first became a major concern. Prior to covid we had been £19!!!!!!!!!!
Suet

suetballs
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older